SwazilandTuberculosis profile
Population  2016 1.3 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.26 (0.15–0.4) 19 (11–30)
Mortality (HIV+TB only) 1.1 (0.71–1.7) 84 (53–123)
Incidence  (includes HIV+TB) 5.4 (3.4–7.8) 398 (252–578)
Incidence (HIV+TB only) 3.8 (2.4–5.4) 280 (181–399)
Incidence (MDR/RR-TB)** 0.66 (0.34–0.98) 49 (25–73)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.31 (0.18–0.43) 2 (1.2–2.8) 2.3 (1.3–3.2)
Males 0.35 (0.2–0.49) 2.7 (1.6–3.9) 3.1 (1.8–4.4)
Total 0.65 (0.38–0.92) 4.7 (2.8–6.6) 5.4 (3.4–7.8)
TB case notifications, 2016  
Total cases notified 3 806
Total new and relapse 3 567
          - % tested with rapid diagnostics at time of diagnosis 82%
          - % with known HIV status 99%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 67% (46–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.27 (0.14–0.42)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 2 649 70%
          - on antiretroviral therapy 2 482 94%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  400
(260–540)
Estimated % of TB cases with MDR/RR-TB 8% (3.1–13) 36% (29–44)  
% notified tested for rifampicin resistance 80% 56% 2 915
MDR/RR-TB cases tested for resistance to second-line drugs   181
Laboratory-confirmed cases MDR/RR-TB: 181, XDR-TB: 14
Patients started on treatment **** MDR/RR-TB: 246, XDR-TB: 13
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 80% 4 148
Previously treated cases, excluding relapse, registered in 2015 67% 291
HIV-positive TB cases registered in 2015 78% 2 929
MDR/RR-TB cases started on second-line treatment in 2014 70% 444
XDR-TB cases started on second-line treatment in 2014 0% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 15%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 15
Funding source: 22% domestic, 78% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data